Peptomyc SL
OMO-103 in Phase 1b clinical trial
BARCELONA, SPAIN / ACCESSWIRE / July 27, 2023 / Peptomyc S.L., a biotech company specialized in the development of protein therapeutics for cancer treatment, announces that it has received full study approval for its new Phase 1b clinical trial, which will evaluate the combination of the first-in-class MYC inhibitor, OMO103, together with the standard of care (SoC) regimen Gemcitabine and Nab-Paclitaxel in metastatic Pancreatic Ductal Adenocarcinoma (PDAC) patients in first line. PDAC is the most common form of pancreatic cancer. Currently, it is the fourth highest cause of cancer mortality worldwide and its incidence is rising steeply. Current therapies offer limited chance of a lasting cure and the five-year survival rate is one of the lowest among the most commonly occurring cancers.
Peptomyc logo
MYC is an oncoprotein deregulated in most -if not all- types of cancers. It is activated in many PDAC cases, where it contributes to aggressiveness of the disease and resistance to treatments. The company recently completed a FIH Phase 1 study of OMO103 in all-comers solid tumor patients, demonstrating excellent safety and promising anti-tumor activity.
Manuela Niewel, MD, PhD, Chief Medical Officer of the company, leading Peptomyc's clinical development, regulatory and medical affairs activities, says: "I am excited to be able to start our new Phase 1b study in PDAC patients. With OMO-103, we hope to address this devastating disease and one of the highest unmet medical needs in the oncology field".
This Phase 1b combination study will be conducted in four sites in Spain. The lead PI will be Dr. Teresa Macarulla at the Vall d'Hebron Institute of Oncology in Barcelona, and she will collaborate with Dr. Andres Muñoz at the Hospital Gregorio Marañon in Madrid, Dr. Mariona Calvo at the ICO-Hospitalet in Barcelona, and Dr. Roberto Pazo at the Hospital Miguel Servet in Zaragoza. The study is planned to start in Q3/2023.
About Peptomyc
Peptomyc (www.peptomyc.com) is a spin-off from VHIO - the Vall d'Hebron Institute of Oncology - and ICREA - the Catalan Institute of Research and Advanced Studies - founded in December 2014 in Barcelona, Spain. The company is focused on the development of innovative cell penetrating peptides (CPPs) targeting the Myc oncoprotein for cancer treatment and based on Dr. Soucek's scientific research in Omomyc (the best direct Myc inhibitor known to date) over the last twenty years. It is the first company to have successfully completed a Phase I clinical trial with a direct MYC inhibitor.
Contact Information
Laura Soucek
CEO
lsoucek@peptomyc.com
+34695207869
SOURCE: Peptomyc SL
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/770698/Peptomyc-Announces-the-Approval-of-Its-Phase-1b-Trial-Testing-OMO-103-in-Combination-With-Standard-of-Care-in-PDAC-Patients
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
OMP Unveils UnisonIQ: the AI Breakthrough Transforming Supply Chain Decision-Making2.10.2025 17:00:00 CEST | Press release
ANTWERPEN, BE / ACCESS Newswire / October 2, 2025 / OMP, a global leader in supply chain planning solutions, today announced the availability of UnisonIQ, a game-changing AI orchestration framework that transforms supply chain decision-making through human-AI synergy. Embedded within OMP's Unison Planning™ platform, UnisonIQ delivers insightful always-on agents that leverage Unison Companion, a generative AI-based assistant, and market-leading AI engines.UnisonIQ Bridging four decades of supply chain innovation with the agentic age As supply chains face unprecedented complexity and volatility, organizations need more than traditional planning tools - they need intelligent systems that can adapt, learn, and act autonomously. Gartner predicts that by 2030, 50% of cross-functional supply chain management (SCM) solutions will use intelligent agents to autonomously execute decisions in the ecosystem. With UnisonIQ, industry leaders can orchestrate decision-centric planning across their glob
Transoft Solutions Receives AiRAP Accreditation2.10.2025 11:00:00 CEST | Press release
Transoft Solutions Named First North American Company to Become an Accredited AiRAP Data Provider for iRAP Global Road Assessments VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / October 2, 2025 / Transoft Solutions, a global leader in transportation engineering, analysis, and operations software, is now officially an accredited AiRAP data provider, reinforcing its support for the International Road Assessment Programme's (iRAP) vision of a world free of high-risk roads. This achievement enables more efficient iRAP Star Rating assessments performed by road safety professionals and practitioners. iRAP's Star Rating methodology uses a predictive, risk-based approach to assess roads universally by reviewing attributes present along the road corridor. The time-consuming traditional method of conducting an iRAP Star Rating involves accredited coders manually reviewing video footage of road, 100m at a time, and coding more than 50 road attributes. These attributes are then processed through
Saudi Electricity Company Appoints Eng. Khalid Bin Salem AlGhamdi as Chief Executive Officer1.10.2025 21:45:00 CEST | Press release
Saudi Electricity Company Appoints Eng. Khalid Bin Salem AlGhamdi as Chief Executive Officer RIYADH, SA / ACCESS Newswire / October 1, 2025 / The Board of Directors of the Saudi Electricity Company (SEC) has announced the appointment of Eng. Khalid bin Salem AlGhamdi as the company's Chief Executive Officer, effective October 1st 2025 . The decision reflects the Board's confidence in the capabilities of Saudi talent and their vital role in advancing the Kingdom's electricity sector, a key enabler of the country's ongoing economic and social transformation.Eng. Khalid bin Salem AlGhamdi Saudi Electricity Company Appoints Eng. Khalid bin Salem AlGhamdi as Chief Executive Officer Commenting on his appointment, Eng. AlGhamdi expressed his deep pride in this trust, extending his sincere gratitude to the Custodian of the Two Holy Mosques, King Salman bin Abdulaziz Al Saud, and to His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister - may God pr
Preservica Launches New AI in Archiving & Digital Preservation Workshop Series1.10.2025 15:00:00 CEST | Press release
OXFORD, UK AND BOSTON, MA / ACCESS Newswire / October 1, 2025 / Preservica, the leader in AI-powered Active Digital Preservation™, is proud to announce the launch of a new AI in Archiving & Digital Preservation - Practitioner Workshop Series. The program is designed to enable archivists, records managers and information professionals to learn, explore and be part of actively shaping the safe and effective use of human-centric AI assistance for archival enrichment, information capture, long-term preservation and enhanced discovery. Led by Preservica's expert Product team and featuring guest speakers from across the industry, the series offers a unique opportunity for participants to: Build practical skills in applying AI with human oversight Collaborate and learn from peers and real-world best practices Experience AI in action and provide feedback on emerging tools Gain control and confidence in how and where AI is applied Over the course of the Series, individual workshops will explore
Innodata to Host Exclusive GenAI Summit in San Francisco October 9, 20251.10.2025 14:30:00 CEST | Press release
Event to be elite gathering of enterprise AI leaders, executives, and innovators charting the path of generative AI NEW YORK, NY / ACCESS Newswire / October 1, 2025 / INNODATA INC. (Nasdaq:INOD), a global data engineering company, today announced it will host the Innodata GenAI Summit on October 9, 2025, at the Contemporary Jewish Museum in San Francisco, California. Designed exclusively for VP+ and C-suite leaders, the summit will bring together executives, AI pioneers, and enterprise innovators to explore how generative AI is transforming industries. The event will feature strategic sessions, executive panels, and curated networking opportunities, with zero vendor pitches and maximum strategic value. "The Innodata GenAI Summit is designed to be a premier executive experience for leaders shaping the future of enterprise AI," said Jack Abuhoff, CEO of Innodata. "We believe the summit will be an environment where decision-makers can share insights, build meaningful connections, and gain
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom